Medivation is expanding the drug beyond prostate cancer treatment, and it plans to conduct a phase 3 trial for triple negative breast cancer (or TNBC) that would start in the second half of 2016. The company is conducting investigational studies for …
(Visited 1 times, 1 visits today)
Comments